# Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma

> **NCT01796002** · PHASE3 · COMPLETED · sponsor: **The Lymphoma Academic Research Organisation** · enrollment: 421 (actual)

## Conditions studied

- Peripheral T-cell Lymphoma

## Interventions

- **DRUG:** Romidepsin + CHOP
- **DRUG:** CHOP

## Key facts

- **NCT ID:** NCT01796002
- **Lead sponsor:** The Lymphoma Academic Research Organisation
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2019-12-13
- **Final completion:** 2022-12-13
- **Target enrollment:** 421 (ACTUAL)
- **Last updated:** 2023-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01796002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01796002, "Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01796002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*